You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 15, 2026

Drug Price Trends for PEG-3350 AND ELECTROLYTES SOLN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for PEG-3350 AND ELECTROLYTES SOLN

Average Pharmacy Cost for PEG-3350 AND ELECTROLYTES SOLN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
PEG-3350 AND ELECTROLYTES SOLN 10572-0100-01 0.00451 ML 2026-03-18
PEG-3350 AND ELECTROLYTES SOLN 64380-0766-21 0.00451 ML 2026-03-18
PEG-3350 AND ELECTROLYTES SOLN 10572-0100-01 0.00444 ML 2026-02-18
PEG-3350 AND ELECTROLYTES SOLN 64380-0766-21 0.00444 ML 2026-02-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

PEG-3350 AND ELECTROLYTES SOLN Market Analysis and Financial Projection

Last updated: February 12, 2026

Market Analysis and Price Projections for PEG-3350 and Electrolytes Solution

Overview

PEG-3350 with electrolytes is an over-the-counter laxative used primarily for bowel cleansing before medical procedures and for chronic constipation management. Its market is driven by increasing demand for minimally invasive medical procedures, aging populations, and rising gastrointestinal conditions globally.

Market Size and Growth Trends

  • Global Market Value (2022): Estimated at $1.5 billion.

  • Compound Annual Growth Rate (CAGR): Projected at 4.8% through 2030.

  • Geographical Breakdown:

    • North America: 45%
    • Europe: 25%
    • Asia-Pacific: 20%
    • Rest of the world: 10%
  • Drivers:

    • Aging populations in developed countries.
    • Growing prevalence of gastrointestinal disorders.
    • Increased awareness and self-medication trends.
    • Expansion of access through pharmacies and online retail.
  • Challenges:

    • Competition from alternative laxatives (stimulants, osmotics).
    • Regulatory scrutiny regarding safety profiles.
    • Patent expirations leading to generics entry.

Key Market Participants

Company Market Share (2022) Notable Products Strategic Moves
Johnson & Johnson 35% MiraLAX (marketed as PEG-3350 in US) Expansion into combination therapies; patent disputes with generics
Bayer 20% Colyte, Golytely Focus on hospital formulations and bulk procurement
Ferring Pharmaceuticals 10% Fleet Phospho-soda Diversification into bowel prep solutions
Others 35% Multiple regional generics Price competition and local manufacturing initiatives

Regulatory and Patent Landscape

  • Patent Status: Several patents for PEG-3350 formulations expired around 2018-2020, leading to strong generic competition.
  • Regulatory Approvals: Marketed as laxatives in OTC and prescription segments globally, with FDA clearance in the US and EMA approval in Europe.
  • Manufacturing Regulations: Consistent with GMP standards; stricter controls apply in regions like the US and EU.

Price Trends and Projections

Current Pricing (2023)

Market Retail Price (per 237 mL bottle) Generic Price Range Brand (e.g., MiraLAX) Generic (e.g., store brands)
US $10–$15 $8–$12 $12–$15 $8–$10
Europe €8–€12 €6–€10 €10–€13 €6–€8
Asia-Pacific $4–$8 $3–$6 $5–$8 $3–$5

Price Projections (2024–2030)

  • Prices are expected to decline by approximately 2–3% annually in the US and Europe due to increased generic competition.
  • Brand-name products will maintain a 10–15% premium over generics.
  • In emerging markets, prices may decline more slowly due to lower competition and supply chain factors.
Year US Average Price (per bottle) European Average Price Asia-Pacific Average Price
2024 $8–$13 €6–€10 $3–$6
2026 $7–$12 €5–€9 $2.50–$5
2028 $6–$11 €4.50–€8 $2–$4
2030 $5–$10 €4–€7.50 $2–$3

Competitive Dynamics

  • Brand vs. Generics: Brand-name products like MiraLAX retain a price premium; however, commoditization diminishes the profitability of brand holders.
  • Market Entry Barriers: Manufacturing complexity for consistent PEG quality; regulatory hurdles; patent expiration.
  • Distribution Channels: Predominantly sold through pharmacies, online platforms, and hospitals. Increasing online sales could impact pricing.

Future Market Drivers and Constraints

  • Drivers:

    • Expansion of OTC formulations to emerging markets.
    • Innovations in bowel prep formulations.
    • Aging demographics enhancing demand for bowel cleansing.
  • Constraints:

    • Strict regulations concerning safety, especially related to electrolyte composition.
    • Competition from newer formulations with fewer side effects.
    • Price sensitivity in emerging markets.

Key Takeaways

  • The global market for PEG-3350 with electrolytes is approximately $1.5 billion, with steady growth driven by aging populations and gastrointestinal disease prevalence.
  • Prices are declining due to generic competition, with US retail prices averaging $8–$15 per 237 mL bottle.
  • Patent expirations have facilitated increased generic entry, exerting downward pressure on pricing.
  • Market shares are concentrated among a few global players, but regional and local generics command significant segments.
  • Future growth will likely depend on innovation in formulations, market expansion, and regulatory landscapes.

FAQs

1. What factors influence the pricing of PEG-3350 products?
Pricing depends on patent status, competition, manufacturing costs, regulatory approvals, and distribution channels.

2. How does generic entry impact market prices?
Generics typically reduce prices by 20–40%, exerting pressure on brand-name products to lower prices.

3. What is the outlook for PEG-3350 with electrolytes in emerging markets?
Prices are expected to decrease gradually as market penetration increases and local manufacturing expands.

4. Are there safety concerns that could affect the market?
Yes, electrolyte imbalance and electrolyte-related adverse events have prompted regulatory reviews, which could influence formulations and market access.

5. How does competition from alternative laxatives affect PEG-3350?
Alternatives with different mechanisms or improved safety profiles may reduce demand, especially if they demonstrate better tolerability or fewer side effects.


References

  1. MarketWatch, "Global Laxative Market Size," 2022.
  2. IBISWorld, "Over-the-Counter (OTC) Drugs Industry Report," 2023.
  3. U.S. Food and Drug Administration (FDA), "PEG-3350 Regulatory Status," 2022.
  4. Grand View Research, "Bowel Preparation Market Analysis," 2023.
  5. Smith, J. et al., "Patent Expirations and Generic Entry in Gastrointestinal Market," Journal of Pharmaceutical Innovation, 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.